GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Short-Term Debt

VGI Health Technology (XNEC:VTL) Short-Term Debt : A$0.00 Mil (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Short-Term Debt?

VGI Health Technology's Short-Term Debt for the quarter that ended in . 20 was A$0.00 Mil.


VGI Health Technology Short-Term Debt Historical Data

The historical data trend for VGI Health Technology's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Short-Term Debt Chart

VGI Health Technology Annual Data
Trend
Short-Term Debt

VGI Health Technology Semi-Annual Data
Short-Term Debt

VGI Health Technology Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


VGI Health Technology Short-Term Debt Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology (XNEC:VTL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines